CD3E and systemic lupus erythematosus: Incidence and severity of DLTs and proportion of relapsed/refractory SLE patients in whom successful manufacturing of the desired dose of anti‐CD19–CD3E–CAR‐T cells is achieved; clinical response for relapsed/refractory SLE 12 weeks post infusion